{"prompt": "['2014-0546', 'August 7, 2017', 'Page 19 of 49', 'TSS) scoring of at least 50% (see Appendix 5) may continue to be treated in the study beyond', '48 weeks until progression or until death from any cause, whichever comes first.', '3.2.', 'Selection of Study Population', 'The diagnosis of MF will be based on bone marrow (BM) aspirate and/or biopsy performed within', '6 weeks prior to Screening. Measurement of JAK2 V617F allele burden in BM samples, if not', 'done within 6 months prior to Screening, must be provided with the Screening BM biopsy/aspirate', 'report.', '3.2.1.', 'Inclusion Criteria', 'Male and female patients who meet all of the following criteria are eligible for enrollment in the', 'trial:', 'a. >18 years of age;', 'b. Diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera (post-PV) MF or', 'post-essential thrombocythemia (post-ET) MF based on the World Health Organization', '(WHO) criteria (Appendix 1) or the IWG-MRT criteria (Appendix 2), which must be', 'confirmed by BM aspirate and/or biopsy within 6 weeks prior to Screening. Measurement', 'of JAK2 V617F allele burden in BM samples, if not done within 6 months prior to', 'Screening, must be provided with the Screening BM biopsy/aspirate report (patients are', 'eligible regardless of JAK2 mutation status);', 'c. Anemia or RBC-transfusion dependence defined as follows:', 'a. Anemia: defined for the purpose of this protocol as 1) a hemoglobin level <10 g/L', 'on every determination over 84 days before study-entry, without RBC-transfusions,', 'or 2) a hemoglobin level <10 g/L on a patient that is receiving RBC-transfusions', 'periodically but not meeting criteria for transfusion-dependent patient as defined', 'below. The baseline hemoglobin value for these subjects is the lowest hemoglobin', 'level during the antecedent 84 days.', 'b.', 'RBC-transfusion-dependence: RBC-transfusion-frequency of>/=2 units PRBC/28', 'days averaged over 84 days immediately pre-study-entry. There must not be any', 'consecutive 42 days without an RBC-transfusion during this interval.', 'd. ECOG performance status of 0, 1 or 2 (see Appendix 3);', 'e. Willing to adhere to the prohibitions and restrictions specified in this protocol (Notation:', \"the subject's willingness to adhere to prohibitions and restrictions must be clearly\", 'communicated in the on-study note.);', 'f. The patient must signed an informed consent form (ICF) indicating that s/he understands', 'the purpose of, and procedures required for, the study and is willing to participate.']['2014-0546', 'August 7, 2017', 'Page 20 of 49', '3.2.2.', 'Exclusion Criteria', 'Patients with any of the following will not be enrolled in the study:', 'a. Ongoing clinically significant anemia due to factors such as known iron, vitamin B12, or', 'folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding;', 'b. Serum ferritin < 50 ng/mL;', 'c.', 'Any active malignancy within the past year, except basal cell or squamous cell skin cancer', 'or carcinoma in situ of the cervix or breast; patients with history of prior malignancies', 'should be free of disease for at least 3 years to be eligible for this study;', 'd. Uncontrolled intercurrent illness, including, but not limited to symptomatic congestive', 'heart failure, unstable angina pectoris, or cardiac arrhythmia;', 'e.', 'Active infection not adequately responding to appropriate therapy;', 'f.', \"Direct bilirubin > 2.0 mg/dL not related to hemolysis or Gilbert's disease;\", 'g. Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 x the upper limit of', 'normal (ULN);', 'h. Serum creatinine > 2.5 mg/dL;', 'i. Ascites requiring active medical management including paracentesis;', 'j.', 'Hyponatremia (defined as serum sodium level < 130 mEq/L);', 'k. Female patients who are pregnant or lactating;', '1.', 'Patients of childbearing potential (ie, women of childbearing potential and men with female', 'partners of childbearing potential) who are unwilling to follow strict contraception', 'requirements (including 2 reliable methods in combination: 1 non-hormonal, highly-', 'reliable method [diaphragm, condoms with spermicidal foam or jelly, or sterilization] plus', '1 additional reliable method [birth control pills, intrauterine device, contraceptive', 'injections, or contraceptive patches]) before entry and throughout the study, up to and', 'including the 30-day non-treatment follow-up period;', 'm. Female patients of childbearing potential who have a positive blood or urine pregnancy test', 'at Screening;', 'n. Major surgery without full recovery or major surgery within 3 weeks of Screening;', 'o. Uncontrolled hypertension (defined as a sustained systolic pressure > 160 mmHg and/or a', 'diastolic pressure > 110 mmHg);', 'p. New onset seizures (within 3 months prior to Screening) or poorly controlled seizures;', 'q. Any other concurrent investigational agent or chemotherapy, radiotherapy, or', 'immunotherapy;', 'r.', 'Chronic use (> 2 weeks) of corticosteroids (prednisone >/= 10 mg/24 hr equivalent) within', '4 weeks of Screening;', 'S.', 'Investigational therapy within 2 weeks of Screening;']\n\n###\n\n", "completion": "END"}